analysis to evaluate the weight loss and increased heart rate associated with the use of phentermine.
METHODS

Inclusion criteria
This study aimed to evaluate the changes in weight and heart rate when phentermine is administered in obese individuals with no drug dependence and underlying disease compared with placebo.
Studies were eligible if they 1) were RCTs; 2) included at least one outcome, weight loss and heart rate; 3) compared between phentermine and placebo for obese patients with no underlying disease, except adjustable hypertension and diabetes; 4) provided sufficient data for analysis; 5) could be available in full-text; 6) were published in English or Korean.
The studies were excluded from the analysis if the above inclusion criterion was not satisfied.
Search strategy and study selection
We searched comprehensive literature using eight electronic databases:
PubMed, EMBASE, Cochrane library, KoreaMed, KMBASE, KISS, NDSL, and RISS through September 2018. The search key word, "Phentermine" in English and Korean, was entered, and MeSH term and logical operator were properly used. Studies were eventually selected after reading the titles, abstracts, and full texts. The studies for this meta-analysis were selected by two independent reviewers. If there was a difference in opinion between the two reviewers, the decision on whether to include the literature was made by consensus.
Quality assessment
The grading system developed by the Scottish Intercollegiate Guideline Network (SIGN) was used to evaluate the quality of selected literatures [15] . The studies were evaluated by two independent reviewers. If there was a difference in opinion between the two reviewers, the decision on whether to include the literature was made by consensus. 
Data extraction and analysis
Data on the following information were extracted from each study:
initial author, publication year and country, number of subjects, followup check, and change in weight and heart rate.
We calculated the effect size (ES) of each study as standardized mean difference (SMD) and corresponding 95% confidence intervals (95% CI) [16] . The ES of each study and overall studies was demonstrated by a forest plot graphically. The test of heterogeneity was performed using I 2 statistics, and 0% to 40% may not be important, 30% to 60% reveals moderate heterogeneity, 50% to 90% is substantial heterogeneity, and 75% to 100% represents considerable heterogeneity [17] . If I 2 ≥ 50%, it was considered heterogeneous [18] . A fixed-effect model was used if heterogeneity was not significant. If it was statistically significant, a random-effects model was performed in the subgroup analysis [19] . Publication bias was assessed by an Egger's test and a funnel plot [20] . Statistical analyses were performed using the Stata/IC ver. 11. (StataCorp LLC, College Station, TX, USA) [21] .
RESULTS
Studies included in the meta-analysis
After searching the electronic databases, 185 literatures were identified, and 31 literatures were selected for review based on the title/abstract. We excluded 20 literatures for full-text review by inclusion/exclusion criteria, and 11 literatures were selected eventually. One literature was separated by two studies by different interventions [22] , and 12 studies were eligible for the meta-analysis ( Figure 1 ). The characteristic features of the studies included in the meta-analysis are given in Table 1 .
As a result of the quality evaluation of the literature, the evidence level of 11 literatures was 1+ (RCT with low risk of bias) and 7 with 1-(RCT with high risk of bias) and 677 subjects (400 in the phentermine group and 277 in the placebo group) were included ( Table 2) .
Meta-analysis of the change in weight
We identified 12 studies involving 677 subjects (400 in the phentermine group and 277 in the placebo group). The change in weight was compared using SMD. The effect size range of each study was -1.96 to -0.81, and the overall effect size was -1.37 (95% CI: -1.55, -1.19). Based on the meta-analysis, weight loss was greater in the phentermine group compared with the placebo group, and such differences were statistically Change in Weight and Heart Rate for Phentermine
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Meta-analysis of the change in heart rate
We identified three studies involving 279 subjects (188 in the phentermine group and 91 in the placebo group). The change in heart rate was compared using SMD. The effect size range of each study was 0.59 to 0.88, and the overall effect size was 0.63 (95% CI: 0.35, 0.92). Based on the analysis, the heart rate in the phentermine group was significantly increased than that in the placebo group (p < 0.001). No significant heterogeneity was observed between the studies (I 2 = 0.0%) (Figure 3 ).
Subgroup analysis
In this study, we conducted a subgroup analysis of weight change in phentermine according to the publication year, country, phentermine dosage, and follow-up check. The overall effect size of 7 studies before A subgroup analysis of heart rate was not required because all 3 studies were published since 2001, and phentermine dosages of all 3 studies were varied. For follow-up check and country, 3 studies can be divided into 2 studies and 1 study, and it is also not required to perform subgroup analysis for only 1 study.
Evaluation of publication bias
Funnel plots were used to detect publication bias, and Egger's test measured funnel plot asymmetry. No evidence of publication bias was identified in weight loss (p > 0.1). Only 3 studies have a result of heart rate increase, thus, publication bias cannot be determined ( Figure 5 ). 
DISCUSSION
Twelve studies involving 677 subjects, including three studies published in Korea, reviewed and performed a meta-analysis to evaluate weight loss and increased heart rate associated with the use of phentermine. In the meta-analysis, the overall effect size of weight loss was -1.37
(95% CI: -1.55, -1.19), demonstrating that phentermine has an effect of weight loss. Haddock et al. [12] conducted a meta-analysis of the weight loss effect associated with the use of phentermine in 2000. However, the study published in 2002 did not include Korean studies because phentermine was approved for marketing in 2004 in Korea. Therefore, this study can be applied to the analysis of weight loss effect of phentermine in Korean.
The overall effect size of the change in heart rate associated with the use of phentermine was calculated in this study. The overall effect size of the change in heart rate was 0.64 (95% CI: 0.35, 0.92), demonstrating that the effect on heart rate associated with the use of phentermine was statistically significant compare with the placebo. The phentermine group showed a greater increase compared with the placebo group, so the study suggests that phentermine can be beneficial for weight loss, whereas the heart rate could be increased.
In this study, the meta-analysis was performed and the overall effect size could be distorted because it is excluded from the meta-analysis if the information required for calculation of the effect size such as standard deviation or standard error is not presented in the systematic review process. In addition, it is important to understand the publication bias when synthesizing studies in meta-analysis. The funnel plot cannot accurately predict the publication bias, and Egger's test is performed when there are 10 or more individual studies. Thus, we cannot make a conclusion about the publication bias. In addition to this, there are limitations in that only literatures published in English and Korean are included in the study.
Nevertheless, to the best of our knowledge, this was the first study to perform a meta-analysis on the effect of increased heart rate associated with the use of phentermine. The result variable of the previous study was weight loss effect only. When body weight is decreased, the RR interval on electrocardiogram becomes wider, and the heart rate becomes slower [23] . However, the result of this study showed an increased heart rate in the phentermine group when body weight was decreased; hence, the trend of heart rate increase was presumed to be because of phentermine intake. Phentermine, which has a similar pharmacological activity to amphetamine, was approved for the short-term treatment of obesity [24] . Phentermine is an appetite suppressant that affects the central nervous system and releases dopamine, norepinephrine, and serotonin.
Heart rate could be increased because phentermine can stimulate the central nervous system [25] .
Phentermine has been associated with heart valve adverse effects in combination with fenfluramine [14] . Phentermine monotherapy is not associated with heart valve adverse events [26] , and phentermine/topiramate combinations have a positive cardiovascular effect [27] . However, Change in Weight and Heart Rate for Phentermine
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http://www.e-jhis.org | 297 phentermine should not be administered to patients with pulmonary arterial hypertension, severe arterial hypertension, past or present cardiovascular disease, or cerebrovascular disease [28] , long-term safety has not been confirmed [29] . Based on the studies included in the metaanalysis, the most frequent adverse drug reaction of phentermine was dry mouth and insomnia, and the incidence of the adverse reactions showed a significant increase in phentermine compared with placebo [22, [30] [31] [32] [33] [34] . In addition, cardiovascular and neurological symptoms, such as hypertension, nervousness, depression, and palpitation, were reported [22, 30, [35] [36] [37] .
In 2012, a young female patient with no underlying disease in Korea was reported to have died from pulmonary hypertension after taking phentermine [38] . Tachyarrhythmia is the main symptom of pulmonary hypertension. Therefore, phentermine should be used as a short-term therapy within 12 weeks based on the drug label, and arrhythmia should be carefully monitored if there are signs of heart rhythm effects, such as heart rate increase, during phentermine intake.
CONCLUSION
We conclude that weight-loss and increased heart rate are associated with the use of phentermine compared with placebo. 
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